<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01601977</url>
  </required_header>
  <id_info>
    <org_study_id>AVAPS AE in COPD</org_study_id>
    <nct_id>NCT01601977</nct_id>
  </id_info>
  <brief_title>Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>AVAPS-AE</acronym>
  <official_title>Validation of the AVAPS AE Algorithm in Chronic Obstructive Pulmonary Disease: A Non-randomised Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Patrick Murphy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Philips Respironics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      COPD continues to be a cause of major morbidity for patients. Those patients who also have
      respiratory failure and obstructive sleep apnoea are at higher risk of exacerbations and
      death and have worse health related quality of life than similar COPD patients without
      respiratory failure.

      Treatment options in this group of patients have been limited and data to support the use of
      machines to assist breathing (non-invasive ventilators) in stable patients are limited. A
      major limitation of these devices has been patient acceptance and achieving sufficient
      control of sleep breathing disturbance.

      Currently devices are set at a fixed pressure to support the breathing throughout the night.
      The new software within the trial device will aim to better match the support provided by the
      machine to that needed by the patient. It is hoped that this may offer enhanced comfort as
      well as superior control of respiratory failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality
      worldwide.

      Treatment options for COPD patients consist of medications, such as bronchodilators and
      anti-inflammatory drugs, pulmonary rehabilitation, long term oxygen therapy (LTOT), lung
      volume reduction surgery and lung transplantation. Studies have shown that bronchodilators
      and anti-inflammatory drugs show minor or no benefit on long term outcomes but rather are
      used mainly for symptomatic relief.1 Pulmonary rehabilitation has been demonstrated to
      improve functional status and symptoms but there is lacking evidence on long term outcomes of
      this therapy. 2 Lung volume reduction surgery and lung transplantation is only appropriate
      for a small number of patients; therefore, there is no demonstration of improved long-term
      survival rate.3, 4

      Of these available therapies, few have been shown to significantly improve long term patient
      outcomes. For the severe COPD patient, LTOT is the only treatment that demonstrated prolonged
      survival in controlled studies. 5, 6 But, despite the effectiveness of LTOT, COPD is still
      characterized by a high morbidity and mortality rate.

      Although the treatment of OSA with CPAP therapy has been associated with reduced hospital
      admissions and exacerbations there are possible adverse consequences on pulmonary mechanics
      due to exacerbating hyperinflation.

      Noninvasive positive pressure ventilation (NPPV) is one therapy that may prove beneficial to
      stable COPD patients. NPPV is the use of positive pressure ventilation administered via a
      nasal or full face mask (that covers both the nose and mouth). This type of ventilation has
      become a well established and increasingly used therapeutic option for patients with
      hypercapnic respiratory failure (HRF) due to COPD.7

      NPPV, used nocturnally, may improve nighttime hypoventilation that is common with COPD
      patients. An improvement in nocturnal hypoventilation would reset the respiratory center
      sensitivity for CO2.8 9 This would result in an improvement in daytime gas exchange and sleep
      quality. It is also known that hyperinflation in patients with COPD increases their work of
      breathing, thus fatiguing the respiratory muscles.10 It has been suggested that by applying
      nocturnal NPPV it would allow the respiratory muscles to rest, resulting in muscle function
      recovery, increased muscle strength, reduced tendency for fatigue and improvement in
      pulmonary function and gas exchange.11

      AVAPS AE AVAPS AE is a mode of therapy (Philips Respironics Inc, Monroeville, PA, USA) with
      potential advantages over the currently established modes of noninvasive positive pressure
      ventilation (CPAP and bilevel therapy). This mode of therapy incorporates AVAPS (automated
      adjustable IPAP setting to maintain target ventilation with a settable rate of change),
      AutoEPAP and Auto Back up Rate. In particular the automated EPAP algorithm will ensure
      optimal upper airway patency without exacerbating hyperinflation.

      In this study, we are evaluating the AVAPS AE mode as compared to the participant's current
      mode of ventilation. We believe that these automated parameters will allow better nocturnal
      ventilatory control to offset the differing elastic and resistive loads imposed by changes in
      body position during sleep. Furthermore, AVAPS AE will counter the changing ventilatory
      requirements due to alterations in lung volumes and airway resistance during different stages
      of sleep. In summary, the AVAPS AE mode will enable automatic adjustment in response to
      ventilatory changes throughout the night.

      Study Objective The objective of this study is to validate the performance of the AVAPS AE
      therapy in COPD-OSA overlap patients during nocturnal ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of Nocturnal Hypoventilation</measure>
    <time_frame>baseline, 6 week assessment</time_frame>
    <description>transcutaneous CO2 recording from overnight sleep study whilst using the device at 6 weeks compared to baseline control when using usual device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>2 weeks</time_frame>
    <description>Severe Respiratory Insufficiency (SRI) questionnaire. Higher scores indicate better quality of life (minimum 0, maximum 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>6 weeks</time_frame>
    <description>Severe Respiratory Insufficiency (SRI) questionnaire. Higher scores indicate better quality of life (minimum 0, maximum 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time</measure>
    <time_frame>baseline, 6 weeks</time_frame>
    <description>Full polysomnography performed at baseline (usual device) and 6 weeks (trial device) to examine TST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control of Nocturnal Hypoventilation</measure>
    <time_frame>2 weeks</time_frame>
    <description>mean tcCO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise Capacity</measure>
    <time_frame>6 weeks</time_frame>
    <description>6 minute walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbation Frequency</measure>
    <time_frame>6 weeks</time_frame>
    <description>patient reported exacerbations following 6 weeks of device usage</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>COPD</condition>
  <condition>OSA</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AVAPS-AE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-invasive ventilation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AVAPS-AE</intervention_name>
    <description>Novel ventilation mode (Omnilab - AVAPS AE algorithm)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Non-invasive ventilation with standard ventilator</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age â‰¥ 21

          -  Diagnosis of COPD

          -  Currently using Bilevel device for COPD-OSA overlap syndrome

          -  Ability to provide consent

          -  Documentation of medical stability by PI

        Exclusion Criteria:

          -  Subjects, who are acutely ill, medically complicated or who are medically unstable.

          -  Subjects in whom PAP therapy is otherwise medically contraindicated.

          -  Subjects who have had surgery of the upper airway, nose, sinus, or middle ear within
             the previous 90 days.

          -  Subjects with untreated, non-OSA sleep disorders, including but not limited to;
             insomnia, periodic limb movement syndrome, or restless legs syndrome (PLMI &gt; 10).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Hart</last_name>
    <role>Principal Investigator</role>
    <affiliation>GSTT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2012</study_first_posted>
  <results_first_submitted>May 3, 2015</results_first_submitted>
  <results_first_submitted_qc>July 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2016</results_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guy's and St Thomas' NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Patrick Murphy</investigator_full_name>
    <investigator_title>Clinical Research Fellow</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Respiratory failure</keyword>
  <keyword>NIV</keyword>
  <keyword>OSA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients approached in ventilation clinic and assessed for trial participation. Patients were recruited and scheduled for trial initiation. Once 10 patients completed the study protocol the remaining recruited patients did not start the assessment period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Initial study period in usual care then switched to novel ventilation with AVAPS-AE algorithm</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10">5 patients consented for study participation but did not attend for study assessments.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Study participants had a pre-existing diagnosis of COPD-OSA and were established on NIV for at least 6 months prior to study enrollement. Patients needed to be clinically stable prior to trial initiation.</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Single arm crossover nonrandomised study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Control of Nocturnal Hypoventilation</title>
        <description>transcutaneous CO2 recording from overnight sleep study whilst using the device at 6 weeks compared to baseline control when using usual device</description>
        <time_frame>baseline, 6 week assessment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Nocturnal Hypoventilation</title>
          <description>transcutaneous CO2 recording from overnight sleep study whilst using the device at 6 weeks compared to baseline control when using usual device</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="1.6"/>
                    <measurement group_id="O2" value="6.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life</title>
        <description>Severe Respiratory Insufficiency (SRI) questionnaire. Higher scores indicate better quality of life (minimum 0, maximum 100)</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life</title>
          <description>Severe Respiratory Insufficiency (SRI) questionnaire. Higher scores indicate better quality of life (minimum 0, maximum 100)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" spread="15"/>
                    <measurement group_id="O2" value="59" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life</title>
        <description>Severe Respiratory Insufficiency (SRI) questionnaire. Higher scores indicate better quality of life (minimum 0, maximum 100)</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life</title>
          <description>Severe Respiratory Insufficiency (SRI) questionnaire. Higher scores indicate better quality of life (minimum 0, maximum 100)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" spread="17"/>
                    <measurement group_id="O2" value="59" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sleep Time</title>
        <description>Full polysomnography performed at baseline (usual device) and 6 weeks (trial device) to examine TST</description>
        <time_frame>baseline, 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time</title>
          <description>Full polysomnography performed at baseline (usual device) and 6 weeks (trial device) to examine TST</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330" spread="72"/>
                    <measurement group_id="O2" value="306" spread="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Control of Nocturnal Hypoventilation</title>
        <description>mean tcCO2</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Control of Nocturnal Hypoventilation</title>
          <description>mean tcCO2</description>
          <units>kPa</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="1.7"/>
                    <measurement group_id="O2" value="6.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exercise Capacity</title>
        <description>6 minute walk test</description>
        <time_frame>6 weeks</time_frame>
        <population>1 patient declined to complete the walking test</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Exercise Capacity</title>
          <description>6 minute walk test</description>
          <population>1 patient declined to complete the walking test</population>
          <units>m</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190" spread="63"/>
                    <measurement group_id="O2" value="175" spread="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbation Frequency</title>
        <description>patient reported exacerbations following 6 weeks of device usage</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intervention</title>
            <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
          </group>
          <group group_id="O2">
            <title>Usual Care</title>
            <description>Usual care including non-invasive ventilation
Usual care: usual care
crossover trial, as per intervention</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbation Frequency</title>
          <description>patient reported exacerbations following 6 weeks of device usage</description>
          <units>exacerbations</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected during device usage.</time_frame>
      <desc>All patients under went clinical review to obtain adverse event data at study assessments</desc>
      <group_list>
        <group group_id="E1">
          <title>Intervention</title>
          <description>Single arm, open labelled study
Omnilab - AVAPS AE algorithm: Nocturnal NIV via Omnilab device using the AVAPS AE algorithm</description>
        </group>
        <group group_id="E2">
          <title>Usual Care</title>
          <description>Usual care including non-invasive ventilation
Usual care: usual care</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Non-randomised controlled study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gill Arbane, Clinical trials coordinator</name_or_title>
      <organization>GSTT</organization>
      <phone>02071888070</phone>
      <email>gill.arbane@gstt.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

